| 翻訳と辞書 |
| Alain de Weck ： ウィキペディア英語版 |
Alain de Weck
Alain L. de Weck, (July 26, 1928 – April 8, 2013), was a Swiss immunologist and allergist.〔''World Who’s Who in Science''. 1968, p. 454.〕 His main scientific contributions were in the area of characterization and prevention of drug allergy.〔Pichler W., Zum Gedenken an Alain L. de Weck (1928 – 2013), ''Allergologie'', Jahrgang 36, Nr. 5/2013, S. 1–2〕 He was the founding director of the Institute of Clinical Immunology at the University of Bern from 1971 to 1993 and authored or co-authored over 600 peer-reviewed publications. He is the recipient of a number of patents〔"Strip for immunological analysis and method for its preparation." European Patent EP 0174247, issued June 5, 1991.〕〔"Method for the determination of sulfidoleukotrienes in tissues and biological fluids and its application in diagnosis of allergies and other inflammatory diseases.", United States Patent 5,487,977, issued January 30, 1996〕 that led to commercial allergy products and services. He served as president of international scientific organizations such as the International Union of Immunological Societies (IUIS) and the International Association for Allergy and Clinical Immunology (IAACI) (now the World Allergy Organization)〔Ruby Pawankar, MD, PhD, FAAAAI, "A Tribute to Alain de Weck", World Allergy Organization, April 15, 2013, http://www.worldallergy.org/UserFiles/Tribute_AlaindeWeck.pdf〕 and was founder and later CEO of the Centre Médical des Grand-Places (CMG) company, acquired by Heska of Fort Collins (Nasdaq: HSKA) in 1997.〔''Heska Acquires CMG Centre Medical of Switzerland'', Press Release, PR Newswire, September 3, 1997〕 In later years he continued his research at the University of Navarra in Spain and wrote on a wide range of topics such as the distinction between science and pseudo-science, the emergence of genetically modified organisms (GMOs) and comparative health care policy.
== Education ==
Alain de Weck grew up in Crans-Montana, attended the Collège Calvin in Geneva and later completed his Baccalauréat in classical studies at the Collège Saint-Michel in Fribourg in 1947. He obtained his M.D. degree from the University of Geneva in November 1953 after medical studies in Fribourg, Lausanne and Geneva. He did his residency in Paris at various hospitals including the Hôpital Bichat, and the Pitié-Salpêtrière Hospital. During this time he was an early resident at the Pavillon Suisse designed by the architect Le Corbusier at the Cité Internationale Universitaire de Paris. Starting in 1954, he came under the tutelage of Professor Werner Jadassohn, then the head of the Department of Dermatology in Geneva, the son of dermatologist, Joseph Jadassohn. There he started investigating the occurrence and root causes of inflammation as well as contact dermatitis due to lymphocytes using the guinea pig nipple as a model for the human skin. This led to the first histopathological demonstration that contact dermatitis is due to sensitized lymphocytes. He then stayed - as the first U.S. Public Health Service funded foreign research fellow from Switzerland - at Barnes Hospital at Washington University in St. Louis from 1958 to 1960 under the guidance of Prof. Herman Eisen. During this time, Alain de Weck made initial contributions to what later became one of his signature research areas: penicillin allergy. In particular he developed penicilloyl-polylysine (PPL) as a test reagent for detecting penicillin allergy.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Alain de Weck」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|